Labcorp Holdings Inc. (LH) Earnings Call Transcripts

Labcorp Holdings Inc.'s Latest Earnings Call - Q2 FY2026

In Q2 2026, Labcorp Holdings Inc. reported revenue of $3.7 billion, a 5.8% increase year-over-year, and adjusted EPS of $4.99, reflecting a 14.9% growth. The company raised its full-year revenue and EPS guidance, signaling strong operational momentum and effective capital allocation strategies. Key drivers included robust performance in diagnostics and biopharma laboratory services, alongside strategic partnerships and technological advancements.

Reported metrics

Guidance from management

Labcorp raised its full-year revenue guidance to 5.4% to 6.3% growth and adjusted EPS guidance to $18.10 to $18.55, reflecting increased confidence in operational performance and market conditions.

What management said

Yes. I would say -- I'll answer the second question first. If you look at some of the patient pay, typically, the second quarter has been a bit higher than other quarters and patient pay includes a lot of things, co-pays, deductibles as well as patients buying direct. We have seen double-digit growth in our Labcorp OnDemand test, which will be included in patient self-pay and the good news about that is patients pay ...

Yes. And just for perspective, right? If you look at our payer mix for the last few years, it has really stayed relatively consistent, and also, as we showed earlier on the call, our bad debt as a percentage of revenue for Diagnostics really continues to be in line with our prior experiences, and which is typically just less than or around like 5% of our revenue. So as you can expect, this is an area of heightened or...

What analysts pressed on

Analysts expressed concerns regarding the impact of ACA changes on volume and potential headwinds from patient responsibility trends. Questions were raised about the competitive landscape and how Labcorp's organic growth compares to peers, particularly in the diagnostics segment.

Main topics on the call

• Revenue Growth — Labcorp's revenue grew 5.8% to $3.7 billion, driven by a 5.5% increase in diagnostics and a 6.5% rise in biopharma laboratory services. Management noted, "Our diagnostics and biopharma laboratory services businesses both...
• Earnings Performance — Adjusted EPS increased 14.9% to $4.99, exceeding expectations. Management highlighted, "We delivered another strong quarter of financial performance," underscoring the company's solid earnings growth.
• Guidance Update — Labcorp raised its full-year revenue guidance midpoint by $42 million and adjusted EPS midpoint by $0.13. Julia Wang stated, "We have raised the midpoint of our enterprise revenue and our adjusted EPS range," reflecting ...
• Specialty Testing Growth — Management reported double-digit growth in specialty testing areas, particularly in oncology and neurology. Adam Schechter emphasized, "We're focusing on high-growth areas like specialty testing," indicating a strategic ...

Read the full Labcorp Holdings Inc. transcript (Q2 FY2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 56 Labcorp Holdings Inc. earnings call transcripts on record, spanning January 14, 2020 to July 30, 2026. Based on this history, Labcorp Holdings Inc. reports quarterly. The most recent call on file is dated July 30, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

LH

Exchange

NYSE

Country

US

Sector

Health Care

Industry

Health Care Providers and Services

Calls on record

56

First call

January 14, 2020

Most recent

July 30, 2026

Reporting cadence

quarterly